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ORIGINAL RESEARCH • SPECIAL REPORT
C
ystic kidney diseases are being diagnosed earlier and 
earlier (1) because of more accessible routine prenatal 
US and advances in US technology. However, diferen-
tial diagnosis often remains a challenge because kidney 
cysts can arise in a large variety of illnesses, imaging pat-
terns evolve over time, and extrarenal features of systemic 
diseases may not be present at a young age. hus, imag-
ing indings for a particular disease in newborns may be 
diferent from those in adolescents, and predicting prog-
nosis or deciding on optimal follow-up intervals can be 
challenging. Imaging can contribute not only to accurate 
diagnosis and prognosis but also to rational management 
of cystic nephropathies. In adults with autosomal domi-
nant polycystic kidney disease (ADPKD), for example, 
total kidney volume measured at MRI has emerged as 
a useful tool with which to identify patients who will 
beneit from treatment (2); however, transfer and adap-
tation of these indings to children is still an important 
research need.
he purpose of this consensus statement is to establish 
uniform standards for choosing the correct imaging mo-
dality and diagnostic criteria for the most common cystic 
kidney diseases in childhood and adolescence and to pro-
pose rational approaches to diagnosis and follow-up in im-
portant clinical settings. he spectrum of diseases covered 
here includes simple cysts; multicystic dysplastic kidneys 
(MCDKs); cystic dysplasia and HNF1B-associated disease; 
autosomal recessive polycystic kidney disease (ARPKD) 
and ADPKD; other ciliopathies, such as nephronophthisis 
and Bardet-Biedl syndrome; acquired cystic kidney disease 
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Kidney cysts can manifest as focal disease (simple and complex kidney cysts), afect a whole kidney (eg, multicystic dysplastic kid-
ney or cystic dysplasia), or manifest as bilateral cystic disease (eg, autosomal recessive polycystic kidney disease [ARPKD] or auto-
somal dominant polycystic kidney disease [ADPKD]). In children, as opposed to adults, a larger proportion of kidney cysts are due 
to genetic diseases (eg, HNF1B nephropathy, various ciliopathies, and tuberous sclerosis complex), and fewer patients have simple 
cysts or acquired cystic kidney disease. he purpose of this consensus statement is to provide clinical guidance on standardization 
of imaging tests to evaluate kidney cysts in children. A committee of international experts in pediatric nephrology, pediatric radiol-
ogy, pediatric US, and adult nephrology prepared systematic literature reviews and formulated recommendations at a consensus 
meeting. he inal statement was endorsed by the European Society of Pediatric Radiology, the European Federation of Societies 
for Ultrasound in Medicine and Biology, the European Society of Pediatric Nephrology, and reviewed by the European Reference 
Network for Rare Kidney Diseases. Main recommendations are as follows: US is the method of choice when assessing pediatric 
kidney cysts, with selected indications for MRI and contrast-enhanced US. CT should be avoided whenever possible because of 
ionizing radiation. Renal US yields essential diagnostic information in many cases. In patients with ARPKD or other ciliopathies, 
abdominal US is needed for diagnosis and screening of portal hypertension. US is usually suicient for follow-up kidney imaging, 
but MRI can be valuable for clinical trials in patients with ADPKD or in older children with tuberous sclerosis complex to evaluate 
both kidney cysts and angiomyolipomas.
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Literature search strategies and ratings are explained in detail in 
Appendix E1 (online). Initial recommendations were developed 
during the workshop via iterative discussion in thematic work-
groups and plenary sessions. Because of the lack of randomized 
trials for almost all questions discussed, formalized grading of 
evidence and recommendations was not performed. A irst draft 
summarizing the consensus recommendations was compiled by 
two researchers (C.G., F.S.) and then reviewed by all members 
of the consensus group. After changes proposed by the academic 
societies were made, the inal draft was reviewed again by all 
members. A list of suggestions for further research can be found 
in Appendix E1 (online).
Technical Issues and General 
Recommendations
Recommendations for Measuring and Describing 
Kidney Cysts and Polycystic Kidneys
Kidney cysts and cystic kidneys should be investigated by 
using US in the first instance, with detailed examination 
and description of the renal parenchyma, urinary tract, 
and cysts.—At US, kidney size should be measured by using 
maximal midsagittal length, as well as width and depth at the 
level of the hilum. Kidney volume should be estimated with 
the prolate ellipsoid formula or may optionally be determined 
by using manual contouring of the kidney and by applying 
the method of disc summation at three-dimensional imaging 
(4). All measurements should be compared with normal lim-
its of locally applicable reference values (5–7). he examina-
tion should document cortical echogenicity (hypo-, iso-, or 
hyperechogenic when compared with liver) and whether cor-
ticomedullary diferentiation is normal, absent, or reversed. 
Comparison with liver echogenicity may be diicult in pa-
tients with concomitant liver disease. Multiple very small 
cysts can also generate abnormal parenchymal echogenicity 
(eg, salt-and-pepper sign at ARPKD) or even solely increased 
echogenicity without visible cysts. When macroscopic cysts 
are present, the number of cysts (one, two to ive, six to 10, 
or more than 10), laterality (uni- or bilateral), location (cor-
tical, medullary, corticomedullary border, ubiquitous), and 
size (maximum diameter of the largest cyst) should be noted. 
he renal hilum and collecting system should be identiied 
to avoid confusion of cysts with dilated calyces due to out-
low obstruction or relux. he complete urinary tract should 
be examined to identify associated disease. Care should be 
taken to examine for abnormal features of the cysts, such as 
signs of bleeding, infection, or malignancy (including, but 
not limited to, calciication, thickened wall, septations, echo-
genic and/or loating material within cysts, or hyperperfusion 
of septations or the cyst wall). However, except for complex 
cysts, neither Doppler US nor contrast material–enhanced 
US are systematically required for characterization of cysts 
(see also the Technical Recommendations for Standard and 
Contrast-enhanced US section).
CT or MRI is not recommended for routine assessment of 
kidney cysts.
Abbreviations
ACKD = acquired cystic kidney disease, ADPKD = autosomal domi-
nant polycystic kidney disease, ARPKD = autosomal recessive polycystic 
kidney disease, AML = angiomyolipoma, CGS = contiguous gene 
deletion syndrome, MCDK = multicystic dysplastic kidney disease, 
TKV = total kidney volume, TSC = tuberous sclerosis complex
Summary
his international consensus statement on imaging of cystic kidney 
diseases in children highlights US as the most useful imaging modal-
ity with which to diagnose a wide variety of underlying disorders and 
for clinical follow-up.
Implications for Patient Care
 n Consensus-based imaging criteria for diagnosis and follow-up 
aim to harmonize and improve standard of care in children with 
kidney cysts.
 n US is the preferred examination method in most children with a 
large variety of cystic kidney diseases or simple cysts.
 n he indications for MRI are limited (eg, for suspicion of malig-
nancy [complex cysts], tuberous sclerosis complex with cysts and 
angiomyolipomas, clinical trials in autosomal dominant polycystic 
kidney disease measuring total kidney volume).
(ACKD); and renal cysts in other diseases, such as tuberous scle-
rosis complex (TSC). Glomerulocystic disease is not covered 
separately here, as it is a purely descriptive diagnosis and a con-
dition that can be caused by a variety of underlying diseases, 
such as autosomal dominant tubulointerstitial disease, HNF1B 
nephropathy, or early TSC, and therefore has little clinical 
value. Cystic tumors are covered briely only in the context of 
complex cysts.
his consensus statement was endorsed by the European So-
ciety of Pediatric Radiology Task Force on Genitourinary Im-
aging, the European Federation of Societies for Ultrasound in 
Medicine and Biology, the European Society of Pediatric Ne-
phrology (working group on inherited kidney disorders), and 
reviewed by the European Reference Network for Rare Kidney 
Diseases (working group on autosomal dominant structural kid-
ney disorders).
Materials and Methods
he Network for Early Onset Cystic Kidney Disease (or 
NEOCYST) is a consortium of clinical, genetic, and transla-
tional researchers devoted to the study of early-onset cystic kid-
ney diseases with a work package devoted to the development 
of guidelines and position papers (3). It is supported by the 
German Ministry of Education and Research, which did not 
inluence the choice of topic or content of the position paper. 
In addition to pediatric nephrologists from the consortium, ex-
ternal experts in pediatric radiology, pediatric US, and kidney 
imaging, as well as adult nephrologists with speciic expertise 
in cystic diseases, were invited to participate. he allocation of 
individual members of the guideline committee to the diferent 
working groups is given in Table E1 (online).
Six researchers (C.G., K.B., A.T., R.T, E.F.A., D.M.) pre-
pared systematic literature reviews in advance of the consensus 
workshop held on September 26, 2017, in Hanover, Germany. 
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tient.—MRI usually requires sedation in smaller children. his 
poses extra risks, especially in patients with pulmonary prob-
lems resulting from gross nephromegaly. Because US yields ad-
equate information in most children with kidney cysts, MRI 
should be reserved for speciic indications, such as suspicion 
of malignancy in complex cysts, detection of AML in patients 
with TSC, and total kidney volume (TKV) measurements (eg, 
in clinical trials of ADPKD). MRI should be preferred to CT 
because of the added importance of avoiding ionizing radia-
tion in children. Referral to a center that specializes in pediatric 
MRI may be necessary.
In patients with impaired renal function, only macrocyclic 
gadolinium chelates should be used if a contrast agent is re-
quired. Gadolinium-containing contrast agents are contraindi-
cated if the estimated glomerular iltration rate is less than 30 
mL/min · 1.73 m2 due to the risk of gadolinium-induced neph-
rogenic systemic ibrosis. In patients younger than 1 year or 
if the estimated glomerular iltration rate is less than 60 mL/
min · 1.73 m2, gadolinium-based contrast agents should be used 
with caution and should not be used twice within 7 days (15). A 
history of allergic reactions should be obtained prior to contrast 
material administration.
T2-weighted sequences are best for use in the visualization of 
cystic involvement (including cyst volume measurement in cases 
of ADPKD), while T1- or T2-weighted sequences can be used 
to delineate the kidney outline and determine TKV. Contrast-
enhanced T1-weighted sequences should only be performed to 
investigate hemorrhage and tumors, and fat-suppression tech-
niques should be used to examine AML. Difusion-weighted 
MRI may be useful in assessing suspected tumorous lesions. 
Further speciic sequences may be necessary to image the liver 
parenchyma and changes associated with portal hypertension.
Assessment of TKV at MRI does not require use of a contrast 
medium; it can be measured with several diferent techniques 
that have only been validated in adults; planimetry is most ac-
curate and should be preferred for clinical trials, while simpliied 
methods (ellipsoid formula or the midsection method) are fast 
and useful to provide a rough estimate of kidney volume or to 
classify adult patients with ADPKD (16).
CT should not be routinely used for investigation of pe-
diatric kidney cysts because US and MRI usually provide 
better contrast resolution without radiation exposure. It 
may be useful in a very small subset of children (eg, 
those with claustrophobia or when MRI is not available 
even with referral). Examination techniques should be 
customized to the pediatric patient.—Because kidney cysts 
are well visualized at US and MRI, there is usually no justii-
cation for exposing children to radiation during their investi-
gation. CT should be avoided and is only acceptable if MRI is 
unavailable or is not possible (eg, a patient with TSC and an 
implanted vagus nerve stimulator) and suspected malignancy, 
bleeding, or complicated infection require urgent treatment 
decisions. If needed in an individual situation, CT protocols 
appropriate to the child should be applied by experienced ra-
diologists and CT radiographers to optimize acquisition data 
relative to the child’s age and weight, and the radiologist or 
US examination of the liver is recommended for initial 
evaluation of cystic kidney disease. Additionally, transab-
dominal genital system US should be performed in female 
patients at first examination.—he liver examination should 
focus on detection of liver cysts, signs of ibrosis (such as irregular 
liver margin, coarse echotexture, or patchy, uniform, or peri-
portal hyperechogenicity), and signs that may indicate portal 
hypertension (such as splenomegaly and decreased or reversed 
portal Doppler low patterns). When a disease with known liver 
involvement is conirmed, US elastography can be used to exam-
ine for liver ibrosis, with normal values for children becoming 
available only recently (8–12). In patients with ARPKD, liver 
US may also reveal mild biliary dilatation or cystic transforma-
tion of the intrahepatic bile ducts (Caroli syndrome).
Transabdominal US of the internal genitalia in female pa-
tients is generally recommended with urinary tract US (13) but 
is especially important in this setting, as HNF1B mutations 
and Bardet-Biedl syndrome are associated with Müllerian duct 
anomalies, such as uterus didelphys, which can lead to ob-
structed hemivagina at irst menstruation.
Technical Recommendations for Standard 
and Contrast-enhanced US
US should be performed by an experienced examiner, 
with special training in pediatric US using the highest 
possible resolution transducers with settings optimized to 
the child.—A curvilinear transducer with a frequency of more 
than 7 MHz is recommended for examinations in the prone 
and supine positions, and a linear transducer with a frequency 
of more than 10 MHz is recommended for examination in the 
prone position. For children who are older, obese, or both, 
lower-frequency transducers may be needed. For optimal vi-
sualization, settings need to be adjusted to the age and weight 
of the patient. US devices capable of color Doppler imaging 
and, ideally, that are also capable of performing elastography 
measurements are recommended.
There are insufficient data in children for the use of con-
trast-enhanced US in cystic kidney disease.—Contrast-
enhanced US has demonstrated good speciicity and sensitivity 
in the examination of complex renal cysts (and suspicious solid 
renal lesions) in adults (Table E2 [online]). However, although 
it may be promising for the future, it has not been evaluated 
for investigation of cystic kidney disease in adults or children. 
Also, there is little expected beneit of contrast-enhanced US 
in this setting, except for tumorous lesions such as fat-poor an-
giomyolipomas (AML), which are potentially better delineated 
(14). Because indications, standard of equipment, and training 
await systematic evaluation, its use is currently restricted to se-
lected cases with complex cysts in experienced centers.
Technical Recommendations for MRI and CT
MRI is not routinely necessary and should be restricted 
to selected cases of pediatric kidney cysts. Examination 
techniques should be customized to the pediatric pa-
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ing is suicient for diagnosis and follow-up, unless atypical 
features develop.
Multicystic Dysplastic Kidney
An MCDK is characterized by replacement of the whole 
kidney with multiple disorganized cysts lacking any 
normal surrounding parenchyma. If functional renal im-
aging is performed, no (or minimal) function is seen.—
MCDK is characterized by a lack of renal parenchyma, al-
though high-resolution probes may show a small amount of 
central echogenic dysplastic undiferentiated tissue. Bilateral 
MCDK is associated with severe oligohydramnios or anhy-
dramnios before birth and usually leads to perinatal death 
because of inadequate lung development. Unilateral MCDK 
may be an isolated inding, but one in three children have 
additional urogenital tract anomalies, and 15% show signs 
of extrarenal anomalies (24). he contralateral kidney should 
be examined thoroughly for dysplasia and other congenital 
uropathies, as this afects overall renal prognosis (25). Atypi-
cal presentation can occur with MCDK in only one moiety 
of a duplex or horseshoe kidney or in an ectopic kidney (26).
In children with unilateral MCDK, renal functional imag-
ing, such as dimercaptosuccinic acid (DMSA) or techne-
tium 99m diethylenetriaminepentacetate (DTPA) scintigra-
phy is not recommended, particularly if the contralateral 
kidney is structurally normal at US with compensatory hy-
pertrophy.—he concordance between US and nuclear medi-
cine studies for MCDK is very high (27). Clinically, there is no 
beneit in showing lack of functional tissue, as nephrectomy is 
no longer routinely performed in most centers (28,29). Com-
pensatory hypertrophy (kidney size more than two standard 
deviations above the mean for one kidney) can occur in utero 
but may take several years to develop (30,31).
In children with unilateral cystic dysplasia or MCDK, the 
contralateral kidney should be monitored with serial US 
to ensure continued appropriate compensatory hyper-
trophy.—Frequency of monitoring depends on the child’s 
age and the degree of compensatory hypertrophy. Local prac-
tices difer over imaging monitoring intervals. Observational 
data suggest that, of those children who develop compensa-
tory hypertrophy, 95% will do so by 3 years of age. However, 
10% still do not show compensatory hypertrophy by 10 years 
of age (30). Additional clinical follow-up for hypertension 
and proteinuria is warranted in all children with only one 
functioning kidney (25).
Children with bilateral cystic dysplasia or unilateral cys-
tic dysplasia/MCDK without contralateral compensa-
tory hypertrophy are at increased risk for progressive 
chronic kidney disease (32) and require follow-up by 
a pediatric nephrologist.—his will include monitoring 
of blood pressure, proteinuria and kidney function. Imaging 
follow-up is unlikely to have therapeutic consequences and 
yields less prognostic information than serial kidney function 
radiographer should limit the exploration ield and radiation 
dose as much as possible. Kidney function and history of al-
lergic reactions to contrast agents should be veriied prior to 
their administration.
Prenatal Suspicion of Cystic Kidney Disease
Cystic kidney diseases often manifest only with hyper-
echogenicity and/or enlarged kidneys prenatally. Oligo-
hydramnios and extrarenal features, such as congenital 
malformations and reduced lung volume, are important 
imaging findings because they affect prognosis. Regular 
monitoring and multidisciplinary care are required dur-
ing pregnancy and postnatally.—Prenatal presentation of 
cystic kidney disease poses numerous challenges to diagnosis 
and management within a tight chronologic framework and 
requires the care of multiple health professionals, which this 
group has addressed in a previous clinical practice recommen-
dation (17).
Disease-specific Recommendations
Disease-speciic diagnostic imaging criteria and recommen-
dations for further imaging are summarized in Figures 1 and 
2.
Simple Cyst
By definition, a simple cyst occurs in a kidney with oth-
erwise normal parenchyma and a normal contralateral 
kidney. It is round, thin-walled, anechoic, nonseptated, 
separate from the collecting system, and has no Doppler 
blood flow related to the cyst.—Simple cysts can occur any-
where within the parenchyma (18–20). hey are much rarer 
in children than in adults, with incidences of less than 0.5% 
in children (19), more than 10% in adults aged 50 years or 
older (21), and more than 30% in adults older than 70 years 
(22). Cysts with additional features, such as solid components, 
septations, or thickened walls, should be considered complex 
cysts. Diferential diagnosis includes the irst manifestation of 
other cystic diseases, caliceal diverticulae (23), hydrocalyx, cys-
tic dysplasia, and—very rarely—hydatid cysts. Posttraumatic 
kidney cysts have been described mainly in adults.
A child with a first-time diagnosis of a single kidney cyst 
requires a detailed medical and family history, thorough 
clinical examination, and at least one follow-up assess-
ment.—Simple kidney cysts are rare in children and may be 
the irst manifestation of an underlying cystic disorder, such as 
genetic cystic disease or, in rare cases, malignancy (18). hus, 
simple cysts should be considered a diagnosis of exclusion. 
Clinical examination and at least one follow-up US examina-
tion should be performed to assess for development of addi-
tional cysts or changes in cyst size or imaging characteristics.
A simple cyst in a child does not need contrast-en-
hanced US, MRI, or CT imaging.—Because of the low 
risk of malignancy, standard US with color Doppler imag-
Gimpel et al
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Figure 1: Summary of findings for a simple cyst and a multicystic dysplastic kidney. (Fig 1 continues)
measurements. hus, imaging does not need to be performed 
regularly unless there are other clinical indications, such as 
infections, pain, or bleeding.
There is no evidence for an increased risk of malignancy 
in MCDK in children and young adults; therefore, moni-
toring solely to exclude malignancy is unnecessary.—
Despite case reports of various malignancies coinciding with 
MCDK (33–36), numerous cohort studies with follow-up 
during childhood have not shown an increased risk of malig-
nancy (Table E3 [online]).
Cystic Dysplasia
Cystic dysplasia is characterized by at least one cyst within 
an abnormal kidney (eg, hyperechogenic parenchyma, 
loss of corticomedullary differentiation, small kidney).—
Other urinary tract abnormalities (such as low impairment [in 
ureteropelvic or vesicoureteral junction stenosis], vesicoureteral 
relux, or posterior urethral valves) may coexist. Cystic dysplasia 
usually involves the whole kidney but can be localized as seg-
mental dysplasia or in a moiety of a duplex kidney. It can occur 
in isolation or as part of many syndromes and chromosomal ab-
errations. Referral to pediatric nephrology is usually required to 
assess for renal function, proteinuria, or hypertension.
Dilated calyces in patients with high-grade obstruction 
or a urinoma may be misdiagnosed as kidney cysts. If 
there is any suspicion of urinary flow impairment, further 
urologic examination is recommended.—While dysplastic 
cysts are usually more subcapsular than dilated calyces, dif-
ferentiation may be diicult even for experienced examiners. 
Obstruction should be ruled out (usually with MAG3 scin-
tigraphy) if there is evidence of collecting system dilatation, 
such as an enlarged renal pelvis or megaureter, or if normal 
surrounding parenchyma can be demonstrated.
HNF1B-associated Disease
The diagnosis of HNF1B-associated disease cannot be 
made with kidney imaging alone and requires genetic con-
firmation.—Renal presentation of mutations in the HNF1B 
gene (also known as transcription factor 2) is variable and non-
speciic (eg, uni- or bilateral cysts, hypo- or dysplasia, agenesis, 
or normal kidney imaging). HNF1B nephropathy is the most 
common cause of kidney hyperechogenicity at prenatal US and 
of kidney cysts in older children (37,38), and its US appear-
ance can mimic that of ARPKD and other cystic nephropathies. 
Many patients have prenatal US kidney abnormalities, but other 
associated prenatal anomalies that may be detected with abdom-
inal US include genital malformations (eg, vaginal and uterine 
Imaging of Kidney Cysts and Cystic Kidney Diseases in Children
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Figure 1 (continued): Summary of findings for cystic dysplasia and HNF1B disease. (Fig 1 continues)
anomalies) and pancreatic anomalies (eg, atrophy and partial 
agenesis) (Table E4 [online]). However, prenatal US is often not 
sensitive enough to routinely show these anomalies.
Because of the autosomal dominant inheritance, kidney 
US in parents (and grandparents, if available) may provide 
useful clues, but 50% of cases carry de novo mutations with 
a negative family history. A family history of maturity-on-
set diabetes of the young type 5 (renal cysts and diabetes 
syndrome), gestational diabetes, hyperuricemia, or concur-
rent hypomagnesemia also makes the diagnosis more likely. 
HNF1B deletions can also be part of chromosome 17q12 
deletion syndrome.
Girls with HNF1B mutations should be examined with trans-
abdominal US of the genital tract.—he reported incidence 
of genital tract abnormalities varies widely between studies 
(Table E4 [online]), with a substantial proportion of female 
subjects having uterine abnormalities. Some of these may be-
come clinically relevant at irst menstruation, justifying ex-
amination of the uterus during abdominal US. Transvaginal 
Gimpel et al
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Figure 1 (continued): Summary of findings for nephronophthisis and Bardet-Biedl syndrome.
US is not recommended in childhood since it is unlikely to 
yield information of therapeutic relevance.
Nephronophthisis
Since US findings of nephronophthisis are nonspecific, the 
diagnosis cannot be based on imaging findings alone. In 
addition, MRI of the kidneys does not help diagnosis or 
management.—Juvenile nephronophthisis usually manifests in 
the form of normal-sized or small kidneys and bilaterally increased 
echogenicity. Since cysts are not universally present, they are not 
mandatory for diagnosis. However, cysts at the corticomedullary 
junction are suggestive of a nephronophthisis-associated renal 
phenotype. Infantile nephronophthisis usually manifests as en-
larged kidneys and cortical microcysts prenatally or in neonates.
Nephronophthisis can manifest as isolated renal disease 
or as part of a syndrome (eg, Joubert, Senior-Løken, Cogan, 
Jeune [asphyxiating thoracic dystrophy], Meckel-Gruber, 
Bardet-Biedl, or Sensenbrenner syndromes); thus, detailed 
clinical examination, including ophthalmologic assessment, 
is required. Diferential diagnosis includes cystic dysplasia 
and autosomal dominant tubulointerstitial kidney disease 
(ADTKD), which can occasionally manifest as medullary 
cysts. (ADTKD is a group of diseases, including those pre-
viously known as medullary cystic kidney disease or famil-
ial juvenile hyperuricemic nephropathy, and may be due to 
UMOD, REN, HNF1b, or MUC1 mutations [39].)
Children suspected of having nephronophthisis should 
undergo abdominal US to look for signs of liver fibro-
Imaging of Kidney Cysts and Cystic Kidney Diseases in Children
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Figure 2: Summary of findings for autosomal recessive polycystic kidney disease and autosomal dominant polycystic kidney disease. (Fig 2 
continues)
sis and portal hypertension.—Liver ibrosis has been 
described in patients with NPHP3, NPHP11, TMEM67, 
ANKS6, and DCDC2 mutations. In the absence of a known 
genetic defect, or in case of mutations in one of the afore-
mentioned genes, abdominal US is recommended to screen 
for liver ibrosis and portal hypertension.
In children suspected of having nephronophthisis and 
disability, developmental delay, or cerebral dysfunc-
tion, cranial MRI is suggested to look for cerebellar ver-
mis hypoplasia.—his “molar tooth” sign (Fig 1) is found 
in patients with Joubert syndrome.
Bardet-Biedl Syndrome
Since imaging findings are nonspecific, the diagnosis 
of Bardet-Biedl syndrome cannot be made on the basis 
of imaging findings alone.—Kidney US in patients with 
Bardet-Biedl syndrome reveals a wide range of abnormali-
ties, including single or multiple uni- or bilateral cysts; 
loss of corticomedullary differentiation; persistent fetal 
lobulation; horseshoe, ectopic, duplex, and absent kid-
neys; and urinary tract malformations (40). Prenatal US 
often shows bilaterally enlarged homogeneously hyper-
echoic kidneys without corticomedullary differentiation 
(41), while in later life the renal phenotype may resemble 
nephronophthisis. Thus, the diagnosis cannot be based on 
imaging findings alone but must include clinical findings 
and genetic analysis; however, imaging can be helpful be-
cause kidney findings may precede other features (eg, obe-
sity, retinal degeneration, and cognitive impairment) and, 
when found in conjunction with polydactyly, are highly 
suggestive. While there are a range of extrarenal findings, 
only a few are seen solely at imaging (eg, uterine malfor-
mations). In later stages of the disease, US quality is some-
times hampered by obesity.
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Figure 2 (continued): Summary of findings for tuberous sclerosis complex, complex cysts, and acquired cystic kidney disease.
Monitoring Children with Nephronophthisis, 
Bardet-Biedl Syndrome, and HNF1B Disease
Regular kidney imaging is not required in children with 
nephronophthisis. However, monitoring for signs of hepatic 
fibrosis is recommended in children with genetic defects 
known to be associated with liver involvement and those with 
an unknown genotype. Monitoring in children with Bardet-
Biedl syndrome and HNF1B-associated disease will depend 
on the type of renal and urinary tract involvement.—Chil-
dren with Bardet-Biedl syndrome who have substantial structural 
kidney or urinary tract abnormalities are at risk for progression 
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should be used to look for signs of portal hypertension, such as 
splenomegaly or abnormal portal Doppler low. In case of con-
irmed liver disease, it may be necessary to perform US (including 
color and duplex Doppler US of the portal vessels and collateral 
circulation) at shorter intervals. US elastography may also become 
a helpful tool to screen for liver ibrosis (50). Careful liver assess-
ment is important prior to kidney transplantation, even if there 
are no clinical symptoms. Patients with substantial bile duct dila-
tation (Caroli syndrome) may be at increased risk for ascending 
cholangitis due to posttransplant immunosuppression. In addi-
tion, children with severe congenital hepatic ibrosis, portal hyper-
tension, or recurrent cholangitis require systematic evaluation for 
combined kidney and liver transplantation (51,52).
Autosomal Dominant Polycystic Kidney Disease
ADPKD is characterized by the gradual development of 
multiple cortical and medullary cysts from early life. Initial 
presentation may be antenatal with subtle cortical hyper-
echogenicity and renal enlargement. Overt cyst develop-
ment may then be detectable at any stage from before 
birth through childhood. The Pei Ravine criteria for US 
diagnosis of ADPKD (53) (three or more uni- or bilateral 
cysts) were derived from patients older than 15 years 
and have low sensitivity in younger children. In patients 
younger than 15 years with a positive family history, the 
presence of at least one kidney cyst, kidney enlargement 
above normal limits, or both should be considered highly 
suggestive of ADPKD.—US is the most useful imaging mo-
dality with which to diagnose ADPKD. While high-resolution 
US and MRI are able to depict more and smaller cysts than 
can standard US in adults, there are no diagnostic criteria for 
these imaging modalities in children (Table E5 [online]). In 
the absence of a known family history of ADPKD, parents and 
grandparents (especially if parents are younger than 40 years) 
of children with kidney cysts, nephromegaly, or both should 
undergo kidney US screening.
Very-early onset ADPKD can manifest as hyperechoic kid-
neys prenatally or in neonates, with a US appearance mim-
icking that of ARPKD or glomerulocystic disease (54). Liver 
involvement is very uncommon but may occur in patients with 
early onset ADPKD. In children with neurologic or cutaneous 
lesions suggestive of TSC, the TSC2/PKD1 contiguous gene 
deletion syndrome (CGS) should be considered. Diferential 
diagnoses of ADPKD include ARPKD, autosomal dominant 
tubulointerstitial kidney disease, HNF1B-associated kidney 
disease, polycystic liver disease, von Hippel-Lindau disease 
(55), and X-linked dominant orofaciodigital syndrome type I 
in female patients. In patients with a negative family history or 
very-early onset ADPKD, the diagnosis should be conirmed 
with genetic testing.
There are important ethical controversies and psychosocial 
issues surrounding the use of presymptomatic imaging to 
diagnose ADPKD in minors, as therapeutic consequences 
may not arise until adulthood.—Systematic diagnostic 
screening with imaging of asymptomatic minors at risk for dis-
to end-stage renal disease in childhood (40). herefore, regular 
screening for urinary tract involvement and voiding dysfunction 
is recommended.
Autosomal Recessive Polycystic Kidney Disease
The classic US appearance of ARPKD is bilaterally enlarged 
kidneys with heterogeneous parenchymal echogenicity 
with a salt-and-pepper pattern. This imaging appearance 
is caused by multiple tiny cysts smaller than or just ap-
proaching the size necessary for detection, which disrupt 
the echo pattern without being clearly distinguishable. 
However, the renal sonographic phenotype can be vari-
able: kidney size may range from normal to massively en-
larged, hyperechogenicity can be limited by the medulla 
or diffuse, and cysts can appear as ductal dilatation or 
as macrocysts of variable size, number, and location.—
Prenatal US may also depict large hyperechogenic kidneys and 
oligohydramnios in severe cases, and these indings are markers 
that the patient is at risk for early need for dialysis (42). Liver 
involvement (congenital hepatic ibrosis, Caroli syndrome, or 
both) is variable (43) and is not tightly correlated with renal 
involvement (44). In classic cases, abdominal US reveals liver 
enlargement, increased or coarsely granulated echogenicity 
with periportal ibrosis (appearing as increased periportal echo-
genicity), intrahepatic bile duct dilatation, cysts, or a combi-
nation of indings. Signs of portal hypertension, such as de-
creased or reversed portal blood low and splenomegaly, may 
be present. In addition, sonographic signs of Caroli syndrome 
(ie, intrahepatic cystic anechoic areas that may contain ibro-
vascular bundles [“central dot sign”], stones, or septa) should 
be assessed. he ibrovascular bundles are composed of portal 
vein and hepatic artery branches, which can be depicted by 
color Doppler US (45).
US is the most useful imaging tool with which to diagnose 
ARPKD, but further information is often necessary to con-
irm the diagnosis (eg, family history, US examination of the 
parents, clinical examination, and genetic analysis). MRI and 
MR cholangiopancreatography should be reserved for use in 
patients with clinical complications of liver disease. Difer-
ential diagnosis includes congenital hepatic ibrosis; atypical 
ADPKD; HNF1B disease; other ciliopathies, such as neph-
ronophthisis, short rib-polydactyly, and Bardet-Biedl, Jeune, 
and Ivemark syndromes; as well as fatty acid oxidation defects 
(46,47). Antenatally, Meckel-Gruber syndrome may have a 
similar renal appearance, but it is always accompanied by se-
vere anomalies of the central nervous system (46).
In children with known ARPKD, annual abdominal US is 
suggested to monitor for signs of portal hypertension. In 
severely affected infants with progressive disease, kidney 
size should be monitored according to clinical needs.—
In patients with ARPKD, there is no clear prognostic value of 
kidney size on kidney function (48,49). hus, kidney imaging 
is mainly useful for decision making prior to potential nephrec-
tomy and transplantation. On the other hand, liver involvement 
is harder to quantify clinically than kidney involvement, and US 
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ease is controversial in current ADPKD guidelines (52,56,57). 
Treatable disease manifestations such as hypertension may arise 
in childhood (58). herapeutic options to slow the progression 
of renal disease are becoming increasingly established in adults 
and may, in selected cases, be considered in children. Parents 
with ADPKD who request imaging of their asymptomatic 
children require genetic counseling. his group will publish 
recommendations on pediatric ADPKD addressing these issues 
in the near future.
In children suspected of having ADPKD without a ge-
netic diagnosis or a clear family history, confirmatory US 
should be performed within 12 months after the initial 
screening. In children with multiple cysts, enlarged (2 or 
more standard deviations larger than the mean) kidneys, 
or both, serial renal US may be helpful but should not 
be performed more frequently than once per year un-
less patients have complications (eg, pain or hematuria). 
MRI should be restricted to rare cases when further imag-
ing is needed and US is not feasible.—Imaging indings 
rarely have therapeutic consequences in pediatric patients with 
ADPKD; thus, clinical monitoring of blood pressure and mi-
croalbuminuria is more important, even though children with 
larger kidneys are at increased risk for hypertension (59–62). In 
patients older than 15 years, TKV at MRI has prognostic value 
for disease progression (63,64), which in adults is relevant for 
decisions about treatment with the vasopressin receptor inhibi-
tor tolvaptan. hus, these recommendations may change in the 
future if a licensed treatment becomes available in asymptomatic 
children, which might necessitate the identiication of patients 
who are at risk for progression to end-stage renal disease.
In pediatric clinical trials in patients with ADPKD, total kid-
ney volume determined with MRI is recommended to mon-
itor progression in cooperative children.—During childhood, 
glomerular iltration rate is nearly always within the normal 
range or even increased due to hyperiltration (58,65); thus, 
a decrease in estimated glomerular iltration rate is a suitable 
marker of disease progression only in the subgroup of children 
with very-early onset ADPKD (66). Height-adjusted TKV at 
MRI is the most established imaging parameter with which to 
monitor disease progression in adults in ADPKD trials (67). 
Correlation of MRI measurements to disease severity in chil-
dren has been performed in only one study, which revealed a 
correlation with current hypertension status and a predictive 
value of cyst volume on development of hypertension (59).
US monitoring of kidney size and cyst number is prefer-
able to MRI in uncooperative children with ADPKD.—In 
contrast to adults, kidneys in children with early ADPKD can 
usually be imaged within one US viewing ield (maximum 
size, approximately 17 cm), which enables adequate measure-
ments for volume calculation to be obtained with the ellipsoid 
formula. Although MRI measurements appear to be slightly 
larger than US kidney volumes in children with ADPKD, dis-
crepancies arise mainly for larger kidneys (4,59). Correlation 
of hypertension to US kidney volume has been demonstrated 
in four pediatric studies (60–62,68). hree-dimensional US is 
a promising new tool for TKV measurement in children with 
ADPKD (4), especially for single kidney volumes less than 
250–300 mL and in other pediatric kidney diseases (69), but 
it requires further validation. Because uncooperative children 
require sedation for MRI, this does not appear warranted in 
a research setting without direct beneit for the child. Use of 
MRI planimetry to measure TKV may be appropriate in ado-
lescents in clinical trials or in children with very large kidneys.
Tuberous Sclerosis Complex
The diagnosis of TSC is based on diagnostic criteria, 
including clinical characteristics and imaging findings 
(mainly on cerebral MRI) (70). Kidney involvement in TSC 
can include AML or kidney cysts, which may be detected 
by using kidney US or MRI.—TSC is usually diagnosed based 
on clinical and cerebral imaging features before renal involve-
ment occurs. AMLs are the most common renal manifestation 
of classic TSC and are considered a major clinical diagnostic 
feature (70). AMLs can often be detected with US, but US may 
not depict fat-poor AMLs. MRI may be needed for rapidly 
growing AMLs or for those with unusual features.
Kidney cysts occur in about 40% of children with classic TSC 
(Table E6 [online]), and the presence of multiple kidney cysts is 
considered a minor clinical diagnostic feature of TSC. In classic 
TSC, kidney cysts are usually small and scarce (thus, they may be 
unilateral and di cult to detect at US in early stages of disease) 
but may precede renal AMLs. Kidney size is initially normal. In 
the absence of an established diagnosis of TSC, diferential diag-
noses include HNF1B-associated disease, ARPKD, and ADPKD.
Patients with the TSC2/PKD1 CGS have a kidney phenotype 
relecting concurrent severe ADPKD, with numerous bilateral 
large cysts (.2.5 cm) that appear early in life, replace the renal 
parenchyma, and lead to kidney enlargement (71–73). When 
numerous kidney cysts are present, AMLs may be di cult to 
detect with US, and MRI may be needed.
For observation of children with known TSC (classic and 
CGS), renal US is suggested until puberty, and MRI is rec-
ommended thereafter.—Kidney US can be used to screen for 
AMLs and to monitor cysts in children with classic TSC and 
TSC2/PKD1 CGS. However, since US can miss AMLs that are fat 
poor or that are in kidneys with numerous cysts, kidney MRI may 
be preferable in children at higher risk for AML (eg, older than 
6 years of age) or with TSC2/PKD1 CGS. Use of a gadolinium-
based contrast agent at MRI is not needed for baseline examina-
tion and should be reserved for cases of unusual presentation, such 
as rapid enlargement, or with clinical features indicating a poten-
tial complication. In patients undergoing brain MRI, the addition 
of kidney MRI can be considered every 1–3 years if it is feasible 
to perform in the same session. Potential risks, such as prolonged 
sedation or excessive examination time, must be considered when 
deciding to perform kidney MRI. In patients with AML 3 cm or 
larger, yearly repeat MRI has been recommended (74). In patients 
without AMLs at initial MRI, this group suggests annual US for 
follow up, with repeat MRI every 2–3 years. In patients older than 
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12 years, we recommend MRI every 1–3 years, depending on 
indings, which is analogous to recommendations for adults (75).
Complex Cysts and Cystic Tumors
Typical signs of malignancy at US are a unilateral single 
cystic mass with a thickened wall, septations, and possi-
bly calcifications or enhanced perfusion at color Doppler 
imaging.—In addition to examining the cystic lesion itself, it 
is important to examine abdominal lymph nodes and evalu-
ate potential tumor iniltration into the surrounding tissues or 
venous system by using standard and Doppler US.
he diferential diagnosis of complex cysts includes cystic ne-
phroma, mesoblastic nephroma, cystic Wilms tumor (nephro-
blastoma), rarer kidney tumors that are infrequently cystic (re-
nal cell carcinoma, sarcoma, or rhabdoid tumors), and parasitic 
cysts. Cystic nephromas are morphologically very similar to 
cystic partially diferentiated nephroblastoma and multilocular 
cystic renal cell carcinoma. Calciications in the lesions or nod-
ules in the septa would be suggestive of cystic partially diferenti-
ated nephroblastoma or cystic renal cell carcinoma, but neither 
US nor CT can be used to conclusively distinguish these entities 
(76). Kidney cysts and cystic tumors can occur in children with 
systemic overgrowth or tumor predisposition syndromes. For ex-
ample, children with Beckwith-Wiedemann syndrome can have 
nephromegaly, kidney cysts, or Wilms tumor (77,78). Children 
with cystic nephroma often have germline DICER1 mutations, 
which also predispose them to several other benign and malig-
nant tumors and require regular monitoring (79). Patients with 
von Hippel-Lindau syndrome can develop simple or complex 
kidney cysts and clear-cell renal cell carcinoma (80).
he Bosniak classiication was originally developed in adults to 
classify kidney cysts as benign, intermediate, or likely malignant 
based on CT characteristics. In children, limited experience sug-
gests that a modiied Bosniak classiication based on US appear-
ance can be used to decide which lesions should be sampled for 
biopsy (81). here appears to be good agreement between US and 
CT classiication of cysts (82) and good interobserver agreement 
of US Bosniak classiication in children (83). his classiication is 
less helpful in von Hippel-Lindau syndrome, as cystic lesions may 
contain microscopic tumors. On the other hand, renal cell carci-
nomas tend to be low grade and slow growing in this group (84).
US should be used in the initial assessment of complex 
cysts, with further imaging performed with contrast- 
enhanced MRI in cases of suspected malignancy. Contrast-
enhanced US may be performed in experienced centers for 
further evaluation.—Contrast-enhanced US appears useful in 
the further characterization of complex cysts in adults (Table E2 
[online]). Its role in children has not been evaluated; however, it 
may hold potential for the future. hus, abdominal MRI (with 
difusion-weighted imaging) should be used for further imaging, 
but abdominal CT is also acceptable (both should be used with 
contrast material; see the warnings already discussed). MRI (or in 
exceptional cases, CT) can also be used to look for small lesions or 
nephrogenic rests in the contralateral kidney, which may not have 
been visible at US. Unless a Wilms tumor is suspected (in which 
case chemotherapy or primary resection are performed), biopsy is 
usually required to diagnose complex cysts.
Acquired Cystic Kidney Disease
ACKD is characterized by multiple small cysts, usually occur-
ring bilaterally in small kidneys, predominantly in the setting 
of end-stage renal disease, or in native kidneys after kidney 
or liver transplantation.—A limited number of older studies 
suggest that the incidence of ACKD in children at dialysis is 22%–
46%, which is comparable to that in adults at dialysis (85–87). 
However, ACKD has also been described in children prior to the 
start of dialysis (88). In adults, incidence increases with duration 
of dialysis but is not associated with race, sex, or underlying renal 
diagnosis (89).
In two cohorts of children after liver transplantation, ACKD 
was observed in 11%–30% of children and was associated with 
reduced kidney function (90,91). ACKD was also reported in a 
case series of seven survivors of stage IV neuroblastoma who had 
undergone whole-body irradiation for bone marrow transplanta-
tion. All of these patients developed chronic kidney disease, two 
developed end-stage renal disease, and one developed renal cell 
carcinoma (92).
In patients on renal replacement therapy and after renal 
transplantation, yearly US follow-up of native kidneys is sug-
gested to monitor for ACKD.—ACKD is an important risk fac-
tor for renal cell carcinoma in adults with end-stage renal disease 
(89). his can also occur during childhood (86), in which case it 
would warrant regular surveillance.
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